SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Milgrom C)
 

Search: WFRF:(Milgrom C) > (2015-2019) > Clinical characteri...

Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement : An international multicenter collaboration

Cheah, Chan Y. (author)
University of Texas,University of Western Australia, Crawley
Bröckelmann, Paul J. (author)
Memorial Sloan-Kettering Cancer Center
Chihara, Dai (author)
University of Texas
show more...
Moskowitz, Alison J. (author)
Memorial Sloan-Kettering Cancer Center
Engert, Andreas (author)
University Hospital of Cologne
Jerkeman, Mats (author)
Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine
El-Galaly, Tarec C. (author)
Aalborg University Hospital
Augustson, Bradley (author)
University of Western Australia, Crawley
Vose, Julie (author)
University of Nebraska Medical Center
Bartlett, Nancy L. (author)
Washington University in St. Louis
Villa, Diego (author)
British Columbia Cancer Agency
Connors, Joseph M. (author)
British Columbia Cancer Agency
Feldman, Tatyana (author)
Hackensack University Medical Center
Pinnix, Chelsea C. (author)
University of Texas
Milgrom, Sarah A. (author)
University of Texas
Dabaja, Bouthaina (author)
University of Texas
Oki, Yasuhiro (author)
University of Texas
Fanale, Michelle A. (author)
University of Texas
show less...
 (creator_code:org_t)
2016-06-20
2016
English 6 s.
In: American Journal of Hematology. - : Wiley. - 0361-8609. ; 91:9, s. 894-899
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Central nervous system (CNS) involvement is rare in patients with Hodgkin lymphoma (HL). Thus, the clinical features and outcomes are not well described. Cases of histologically confirmed CNS HL diagnosed between 1995 and 2015 were retrospectively identified in institutional (n = 7), national (n = 2), and cooperative group (n = 1) databases. We screened 30,781 patients with HL in our combined databases and identified 21 patients meeting eligibility criteria, an estimated frequency of 0.07%. CNS involvement was present at initial diagnosis in 10 patients (48%) and a feature of relapsed/refractory disease in 11 (52%). Among these 11 patients, the median time from initial diagnosis of HL to development of CNS involvement was 1.9 years (range 0.4–6.6) and the median number of prior lines of therapy was 2 (range 1–7). Altogether, treatments included radiation, multiagent systemic chemotherapy, combined modality therapy, and subtotal resection. The overall response rate was 65%. After a median follow-up of 3.6 years (range 0.8–13.2) from diagnosis of CNS HL, the median PFS and OS were 7.6 and 29 months, respectively. CNS involvement as a feature of relapsed/refractory disease was adversely prognostic for both PFS and OS; however, four patients remain alive and free of relapse at 7–78 months follow-up. CNS involvement in HL is exceedingly rare and has a distinct clinical presentation with predilection for parenchymal lesions with dural extension. Around one-quarter of patients, mostly with CNS involvement at initial HL diagnosis, experience prolonged disease-free survival. Am. J. Hematol. 91:894–899, 2016.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Publication and Content Type

art (subject category)
ref (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view